Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: Implication for maintenance immunotherapy

Leukemia

Volumn 24, Issue 7, 2010, Pages 1310-1316

  Ysebaert, L ^a,b,c   Gross, E ^a,b   Kuhlein E ^d   Blanc, A ^a,b   Corre, J ^c   Fournie J J ^a,b   Laurent, G ^a,b,c   Quillet Mary, A ^a,b  

^a INSERM   (France)

^b France   (France)

^c CHU PURPAN   (France)

^d CHU RANGUEIL   (France)

Author keywords

antibody dependent cellular cytotoxicity; FCR; immune recovery; MRD; NK; RTX

Indexed keywords

CD20 ANTIBODY; CYCLOPHOSPHAMIDE; FLUDARABINE; INTERLEUKIN 2; RITUXIMAB; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; VIDARABINE;

ADULT; AGED; ARTICLE; B CELL LEUKEMIA; BONE MARROW BIOPSY; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POPULATION; CLINICAL ARTICLE; CYTOTOXICITY; DISEASE CONTROL; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNE STATUS; IMMUNOMODULATION; IMMUNOTHERAPY; LEUKEMIA CELL; LEUKOCYTE COUNT; LYMPHOCYTOTOXICITY; MALE; MINIMAL RESIDUAL DISEASE; MONOCYTE; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; PRIORITY JOURNAL; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; IMMUNOLOGY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; IMMUNOMODULATION; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PROGNOSIS; SURVIVAL RATE; VIDARABINE;

EID: 77954659957     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.89     Document Type: Article

References (25)

1. Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112:975-980.
2. Hallek M, Fingerle-Rowson G, Fink A, Busch R, Mayer J, Hensel M et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improve response rates and progressionfree survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leulemia (CLL). Blood 2008;112 abstract no. 325.
3. Milligan DW, Kochethu G, Dearden C, Matutes E, MacConkey C, Catovski D. High incidence of myelodysplasia and secondary leukaemia in the UK medical research council pilot of autografting in chronic lymphocytic leukaemia. Br J Haematol 2006;133:173-175.
4. Cheson BD, Vena DA, Barrett J, Freidin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukaemia. J Clin Oncol 1999;17:2454-2460.
5. Tam CS, Seymour JF, Miles Prince H, Kenealy M, Wolf M, Januszewicz EH et al. Treatment-related myelodysplasia following fludarabine combination therapy. Haematologica 2006;91:1546-1550.
6. Ravandi F, O'Brien S. Immune defects in patients with chronic lymphocytic leukemia. Cancer Immunol Immunother 2006;55:197-209.
7. Burton JD, Weitz CH, Kay NE. Malignant chronic lymphocytic leukemia B cells elaborate soluble factors that down-regulate T cell and NK function. Am J Hematol 1989;30:61-67.
8. Maki G, Hayes GM, Naji A, Tyler T, Carosella ED, Rouas-Freiss N et al. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G. Leukemia 2008;22:998-1006.
9. Gertner-Dardenne J, Bonnafous C, Bezombes C, Capietto AH, Scaglione V, Ingoure S et al. Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies. Blood 2009;113:4875-4884.
10. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446-5456.
11. Rawstron AC, Villamor N, Ritgen M, Böttcher S, Ghia P, Zehnder JL et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007;21:956-964.
12. Rawstron AC, de Tute R, Jack AS, Hillmen P. Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukaemia-specific assay for use in rituximab-containing regimens. Leukemia 2006;20:2102-2110.
13. Keating MJ, O'Brien S, Lerner S, Koller C, Beran M, Robertson LE et al. Long-term follow-up of patients with chronic lymphocytic leukaemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998;92:1165-1171.
14. Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005;106:2018-2025.
15. Lundin J, Porwit-MacDonald A, Rossmann ED, Karlsson C, Edman P, Rezvany MR et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 2004;18:484-490.
16. Beum PV, Lindorfer MA, Taylor RP. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving. J Immunol 2008;181:2916-2924.
17. Moreno C, Villamor N, Colomer D, Esteve J, Giné E, Muntañola A et al. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood 2006;107:4563-4569.
18. Ritgen M, Böttcher S, Stilgenbauer S, Bunjes D, Schubert J, Cohen S et al. Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial. Leukemia 2008;22:1377-1386.
19. Oelschlaegel U, Bornhäuser M, Kiani A, Platzbecker U, Röllig C, Wermke M et al. Flow cytometric detection of minimal residual disease one year post allogeneic stem cell transplantation predicts outcome in patients with B-CLL. Blood 2009;114 abstract no. 202.
20. Egle A, Weiss L, Gassner F, Russ G, Pleyer L, Gunsilius E et al. Minimal residual disease (MRD) and T/NK cell dynamics during Fludarabine, Cyclophosphamide plus Rituximab (FCR) followed by Fludarabine plus Rituximab (FR) and remission maintenance therapy with Rituximab in previously untreated B-chronic lymphocytic leukemia (B-CLL): risk factor stratification in the Chairos study. Blood 2008;112 abstract no. 3175.
21. Ghia P, Chiorazzi N, Stamatopoulos K. Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation. J Intern Med 2008;264:549-562.
22. Golay J, Manganini M, Facchinetti V, Gramigna R, Broady R, Borleri G et al. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica 2003;88:1002-1012.
23. Moga E, Alvarez E, Cantó E, Vidal S, Rodríguez- Sánchez JL, Sierra J et al. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma. Exp Hematol 2008;36:69-77.
24. Gowda A, Roda J, Hussain SR, Ramanunni A, Joshi T, Schmidt S et al. IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibodydependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. Blood 2008;111:4723-4730.
25. Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008;14:4650-4657.